- Dapagliflozine2013 | First Faculty of Medicine
- Dapagliflozin2013 | Faculty of Medicine in Hradec Králové
- Dapagliflozin and its position in DM 2 treatment2017 | Faculty of Medicine in Pilsen
- Dapagliflozin: aspects of clinical use2014 | Second Faculty of Medicine
- An original patient and dapagliflozin treatment2016 | Faculty of Medicine in Pilsen
- Dapagliflozin - a new option in treating type 2 diabetes mellitus2015 | Second Faculty of Medicine
- Dapagliflozin - new antidiabetic with a triple beneficial effect on CV risk factors2015 | First Faculty of Medicine
- Fixed-dose combination of dapagliflozin and metformin in the early treatment of type 2 diabetes mellitus2016 | First Faculty of Medicine
- Fixed combination metformin, dapagliflozin - the advantages of fixed combinations2015 | Second Faculty of Medicine
- Dapagliflozin, diabetes mellitus and cardiovascular disease eyes internist2015 | First Faculty of Medicine
- Results of dapagliflozin treatment in patients with type 2 diabetes poorly controlled metformin2012 | Second Faculty of Medicine
- Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin2022 | First Faculty of Medicine
- Instead dapagliflozinu in treating type 2 diabetes mellitus. First Clinical Experience2014 | Second Faculty of Medicine
- Dapagliflozin in the treatment of heart failure with preserved ejection fraction2023 | Publication without faculty affiliation
- Dapagliflozin prokázal kardiovaskulární bezpečnost u diabetiků 2. typu2018 | Second Faculty of Medicine
- Gliflozins and treatment of diabetes2016 | Second Faculty of Medicine
- Výzkumná zpráva Fakultní nemocnice ke klinickému hodnocení D1693C00001Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: D1693C00001Publication without faculty affiliation
- Commentary to study2016 | Second Faculty of Medicine
- Tři schválené indikace jedné molekuly: dapagliflozin2023 | Faculty of Medicine in Hradec Králové
- Complex efficiency dapagliflozinu in combination therapy with metformin in type 2 diabetes mellitus2015 | Second Faculty of Medicine
- Dapagliflozin zpomaluje progresi renální insuficience nejen u diabetiků, ale i u nediabetiků s chronickým onemocněním ledvin2020 | First Faculty of Medicine
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction2022 | First Faculty of Medicine
- Dapagliflozin a studie DECLARE-TIMI 58: základní charakteristika2018 | First Faculty of Medicine
- Inhibition of SGLT-2 as a new approach in the treatment of type 2 diabetes mellitus2013 | First Faculty of Medicine, Third Faculty of Medicine
- Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial2022 | First Faculty of Medicine
- Additional options in diabetes treatment - gliflozins2014 | Faculty of Medicine in Hradec Králové
- Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index2021 | First Faculty of Medicine
- Dapagliflozin působí protektivně nejen u diabetiků, ale i u nediabetiků2020 | First Faculty of Medicine
- New drugs in type 2 diabetes mellitus therapy2013 | Second Faculty of Medicine